GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aion Therapeutic Inc (XCNQ:AION) » Definitions » Debt-to-Revenue

Aion Therapeutic (XCNQ:AION) Debt-to-Revenue : 2.29 (As of Jan. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Aion Therapeutic Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Aion Therapeutic's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was C$2.04 Mil. Aion Therapeutic's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was C$0.00 Mil. Aion Therapeutic's annualized Revenue for the quarter that ended in Jan. 2024 was C$0.89 Mil. Aion Therapeutic's annualized Debt-to-Revenue for the quarter that ended in Jan. 2024 was 2.29.


Aion Therapeutic Debt-to-Revenue Historical Data

The historical data trend for Aion Therapeutic's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aion Therapeutic Debt-to-Revenue Chart

Aion Therapeutic Annual Data
Trend Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
Debt-to-Revenue
Get a 7-Day Free Trial N/A N/A N/A N/A N/A

Aion Therapeutic Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A 2.29

Competitive Comparison of Aion Therapeutic's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Aion Therapeutic's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aion Therapeutic's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aion Therapeutic's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Aion Therapeutic's Debt-to-Revenue falls into.



Aion Therapeutic Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Aion Therapeutic's Debt-to-Revenue for the fiscal year that ended in Apr. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.826 + 0) / N/A
=N/A

Aion Therapeutic's annualized Debt-to-Revenue for the quarter that ended in Jan. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(2.035 + 0) / 0.888
=2.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Jan. 2024) Revenue data.


Aion Therapeutic Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Aion Therapeutic's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Aion Therapeutic (XCNQ:AION) Business Description

Traded in Other Exchanges
Address
700 West Georgia Street, Suite 2200, Vancouver, BC, CAN, V7Y 1K8
Aion Therapeutic Inc is in the business of research and development, treatment, data mining, and state of the art artificial intelligence techniques, focused on the development of combinatorial pharmaceuticals, nutraceuticals, and cosmeceuticals utilizing compounds from cannabis, psychedelic mushrooms, fungi, natural psychedelic formulations, and other medicinal plants in a legal environment for this type of discovery.
Executives
Ismail Abdul Fattah Director or Senior Officer of 10% Security Holder

Aion Therapeutic (XCNQ:AION) Headlines

No Headlines